World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 16 December 2017
Main ID:  NCT02458196
Date of registration: 15/04/2015
Prospective Registration: Yes
Primary sponsor: Peking Union Medical College Hospital
Public title: Study of Treatment Response on IgG4 Related Disease (IgG4RD)
Scientific title: A Randomized Trial of Treatment in Patients With IgG4-Related Disease
Date of first enrolment: April 2015
Target sample size: 60
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
Name:     Xuan Zhang, Professor
Telephone: 861069155821
Name:     Wen Zhang, Professor
Telephone: 861069158795
Name:     Wen Zhang, Professor
Affiliation:  Peking Union Medical College Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

- Males and females

- Aged 18 to 70 years old with informed consent

- All patients must meet the following diagnostic criteria of IgG4RD (2011):

1. swelling, sclerosing and inflammatory involvement of one or more organ, including
sclerosing pancreatitis, sialadenitis (Mikulicz disease), sclerosing cholangitis,
inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial
nephritis, hypophysitis, sclerosing dacryoadenitis, inflammatory aortic aneurysm,
lymphadenopathy, or other inflammatory conditions;

2. elevated serum IgG4 (>1.35 g/L);

3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma
cell infiltration (and IgG4+ plasma cells on immunohistology when performed).
Patients fulfill 1)+2)+3) are diagnosed as definite IgD4RD, 1)+2): possible
IgG4RD; 1)+3): probable IgG4RD;

4. exclusion of other diseases.

Exclusion Criteria:

- Patients will not be included if meets any of the following criteria:

1. Patients who were diagnosed as other autoimmune diseases;

2. Patients who were diagnosed as malignant diseases;

3. Pregnant and lactating women;

4. Active infection: HIV, HCV, HBV, TB;

5. Serious organ function failure, expected life time less than 6 months.

6. Presenting with Mikulicz disease without other manifestations.

Age minimum: 18 Years
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Autoimmune Disease
Drug: Prednisone
Drug: Prednisone and Mycophenolate mofetil
Primary Outcome(s)
Complete and partial response rate at 3, 6, 9 and 12 months. [Time Frame: Up to 12 months]
Secondary Outcome(s)
Disease response at 3, 6, 9 and 12 months. [Time Frame: Up to 12 months]
Number of participants with adverse effect [Time Frame: Up to 12 months]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history